T 细胞急性淋巴细胞白血病：临床开发中有前景的实验性药物

INTRODUCTION: Despite advances in treatment approaches in acute lymphoblastic leukemia (ALL), the prognosis of adults with newly diagnosed T-ALL remains poor, as well as that of adults and children with relapsed disease. Novel targeted therapies are therefore needed. AREAS COVERED: This review summarizes promising emerging strategies for the treatment of T-ALL. EXPERT OPINION: The recent molecular characterization of T-ALL has led to the identification of new therapeutic targets.

Small-molecules inhibitors and other targeted therapies have therefore been recently developed and are currently under clinical investigations. Similarly, first studies involving monoclonal antibodies and chimeric antigen receptor (CAR) T cells have shown encouraging results. Improvement of outcome with these novel approaches, eventually combined with current standard chemotherapy, is therefore expected in a near future in T-ALL.